Antiepidermal growth factor receptor therapy for glioblastoma
Patient or population: Adult (aged ≥ 18 years) with histologically confirmed glioblastoma diagnosis, either newly diagnosed or with recurrent disease were included. Intervention: anti‐EGFR therapy (including anti‐EGFR monoclonal antibodies, EGFR tyrosine kinase inhibitors or vaccines) alone or in combination with standard of care Comparison: standard of care or placebo
Outcomes	Illustrative comparative risks		Relative effect (95% CI)	No of participants (studies)	Certainty of evidence (GRADE)	Comment
	Assumed risk	Corresponding risk
Overall survival
Progression‐free survival
Adverse effects
Quality of life
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk(and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; EGFR: epidermal growth factor receptor.
GRADE Working Group grades of evidence High certainty: further research is very unlikely to change our confidence in the estimate of effect. Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low certainty: we are very uncertain about the estimate.